Radioactive lipiodol takes aim at inoperable liver tumors

NCT ID NCT05797870

Terminated Disease control Sponsor: Center Eugene Marquis Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This phase II trial tests a targeted radiation therapy called 188Re-SSS lipiodol for people with liver cancer that cannot be surgically removed. The treatment delivers radiation directly to the tumor through the liver's blood vessels. The study aims to see how many patients' tumors shrink within six months. Only 16 participants were planned, but the trial is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 188Re-SSS lipiodol (radioactive substance delivered directly to the liver tumor)
What this could lead to: If it works, this could offer a new treatment option for people with liver cancer that cannot be removed by surgery.
What could go wrong: This is a small, early-phase trial (only 16 people) and is currently suspended. The treatment involves radiation, which can cause side effects like liver damage or fatigue. Success is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA NON-RESECTABLE

Contacts and locations

Locations

Centre de Lutte contre le Cancer Eugène Marquis

Rennes, Brittany Region, 35042, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.